NovaBridge Biosciences (NBP) Status update summary

Company and Business Overview

• Operates a global hub-and-spoke biotech platform bridging Asian innovation to global markets, focusing on capital-efficient asset acquisition and rapid proof-of-concept.

• Maintains a strong balance sheet with $228 million in cash, providing operational runway through 2028 and supporting key clinical milestones.

• Leadership team includes experienced executives and renowned ophthalmology specialists.

• NovaBridge is the majority shareholder of Visara, which controls global rights to VIS-101 outside Greater China and certain Asian countries.

• Pipeline includes VIS-101, givastomig for gastric cancer, and ragistomig for solid tumors.

VIS-101 Clinical Data and Development

• VIS-101 is a tetravalent bispecific antibody targeting VEGF-A and ANG-2, designed for best-in-class durability and efficacy in retinal vascular diseases.

• Phase 2a trial in wet AMD (n=38) showed mean BCVA improvement >10 ETDRS letters and median CST reduction of 100-150 μm after three loading doses.

• Up to 70% of treatment-naive patients were retreatment-free at four months, and nearly half at six months post-loading dose.

• VIS-101 demonstrated a favorable safety profile with no dose-limiting toxicities; adverse events were mild and manageable, with 0% in the 3 mg group and 8% in the 6 mg group.

• The study enrolled 38 patients in China, randomized 2:1 between 6 mg and 3 mg doses, with similar baseline demographics.

Market Opportunity and Competitive Positioning

• The branded anti-VEGF-A market exceeds $15B, with over 57 million people affected globally by wet AMD, DME, and RVO.

• VIS-101's durability and efficacy compare favorably to leading therapies such as faricimab, with fewer loading doses and extended treatment-free intervals.

• VIS-101 offers double the anti-VEGF and 17 times the anti-ANG-2 inhibition compared to faricimab.

• Predictive modeling and clinical data suggest VIS-101 may offer class-leading durability and robust vision improvement.

• VIS-101's emerging product profile offers tangible benefits for patients with high treatment burdens from current therapies.